Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001181431-15-008835
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-07-29 16:46:59
Reporting Period:
2015-07-27
Filing Date:
2015-07-29
Accepted Time:
2015-07-29 16:46:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1407038 Bg Medicine Inc. BGMD In Vitro & In Vivo Diagnostic Substances (2835) 043506204
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1131095 Agtc Advisors Fund Lp C/o Flagship Ventures
One Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
1222012 Noubar Afeyan C/o Flagship Ventures
One Memorial Drive, 7Th Floor
Cambridge MA 02142
Yes No Yes No
1400240 Flagship Ventures Management, Inc. C/o Flagship Ventures
One Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
1400241 Newcogen Group, Inc. C/o Flagship Ventures
One Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
1419730 Agtc Partners, L.p. C/o Flagship Ventures
One Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-07-27 3,256 $0.14 57,010 No 4 X Indirect Held by AGTC Advisors Fund, L.P.
Common Stock Disposition 2015-07-27 206 $2.27 56,804 No 4 S Indirect Held by AGTC Advisors Fund, L.P.
Common Stock Acquisiton 2015-07-27 254 $0.14 57,058 No 4 X Indirect Held by AGTC Advisors Fund, L.P.
Common Stock Disposition 2015-07-27 16 $2.27 57,042 No 4 S Indirect Held by AGTC Advisors Fund, L.P.
Common Stock Acquisiton 2015-07-27 254 $0.14 57,296 No 4 X Indirect Held by AGTC Advisors Fund, L.P.
Common Stock Disposition 2015-07-27 16 $2.27 57,280 No 4 S Indirect Held by AGTC Advisors Fund, L.P.
Common Stock Acquisiton 2015-07-27 254 $0.14 57,534 No 4 X Indirect Held by AGTC Advisors Fund, L.P.
Common Stock Disposition 2015-07-27 16 $2.27 57,518 No 4 S Indirect Held by AGTC Advisors Fund, L.P.
Common Stock Acquisiton 2015-07-27 254 $0.14 57,772 No 4 X Indirect Held by AGTC Advisors Fund, L.P.
Common Stock Disposition 2015-07-27 16 $2.27 57,756 No 4 S Indirect Held by AGTC Advisors Fund, L.P.
Common Stock Acquisiton 2015-07-27 508 $0.14 58,264 No 4 X Indirect Held by AGTC Advisors Fund, L.P.
Common Stock Disposition 2015-07-27 32 $2.27 58,232 No 4 S Indirect Held by AGTC Advisors Fund, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 X Indirect Held by AGTC Advisors Fund, L.P.
No 4 S Indirect Held by AGTC Advisors Fund, L.P.
No 4 X Indirect Held by AGTC Advisors Fund, L.P.
No 4 S Indirect Held by AGTC Advisors Fund, L.P.
No 4 X Indirect Held by AGTC Advisors Fund, L.P.
No 4 S Indirect Held by AGTC Advisors Fund, L.P.
No 4 X Indirect Held by AGTC Advisors Fund, L.P.
No 4 S Indirect Held by AGTC Advisors Fund, L.P.
No 4 X Indirect Held by AGTC Advisors Fund, L.P.
No 4 S Indirect Held by AGTC Advisors Fund, L.P.
No 4 X Indirect Held by AGTC Advisors Fund, L.P.
No 4 S Indirect Held by AGTC Advisors Fund, L.P.
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrant to Purchase Common Stock (right to buy) Disposition 2015-07-27 3,256 $0.00 3,256 $0.14
Common Stock Warrant to Purchase Common Stock (right to buy) Disposition 2015-07-27 254 $0.00 254 $0.14
Common Stock Warrant to Purchase Common Stock (right to buy) Disposition 2015-07-27 254 $0.00 254 $0.14
Common Stock Warrant to Purchase Common Stock (right to buy) Disposition 2015-07-27 254 $0.00 254 $0.14
Common Stock Warrant to Purchase Common Stock (right to buy) Disposition 2015-07-27 254 $0.00 254 $0.14
Common Stock Warrant to Purchase Common Stock (right to buy) Disposition 2015-07-27 508 $0.00 508 $0.14
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2015-07-28 No 4 X Indirect
0 2015-09-08 No 4 X Indirect
0 2015-09-28 No 4 X Indirect
0 2015-11-14 No 4 X Indirect
0 2015-12-15 No 4 X Indirect
0 2016-03-10 No 4 X Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 43,930 Direct
Common Stock 786,970 Indirect Held by Applied Genomic Technology Capital Fund, L.P.
Common Stock 2,508 Indirect Held by Atlast LP
Common Stock 441,072 Indirect Held by Flagship Ventures Fund 2007, L.P.
Footnotes
  1. Share and price per share amounts have been adjusted to reflect a 1-for-4 reverse split of the Issuer's common stock on July 8, 2015.
  2. On July 27, 2015, AGTC Advisors Fund, L.P. ("AGTCA") exercised warrants to purchase 3,256 shares of Common Stock for $0.14 per share. AGTCA exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 206 of the warrant shares to pay the exercise price and issuing to AGTCA the remaining 3,050 shares.
  3. NewcoGen Group, Inc. ("NG") is the general partner of AGTC Partners, L.P., which is the general partner of AGTCA and Applied Genomic Technology Capital Fund, L.P. ("AGTCF", and together with AGTCA, the "AGTC Funds"). NG is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship"). Noubar B. Afeyan, Ph.D. is the director of Flagship and may be deemed to beneficially own the securities held by the AGTC Funds. Dr. Afeyan disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
  4. The price reflects the average of the closing prices of the Common Stock over the five day period prior to the exercise date.
  5. On July 27, 2015, AGTCA exercised warrants to purchase 254 shares of Common Stock for $0.14 per share. AGTCA exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 16 of the warrant shares to pay the exercise price and issuing to AGTCA the remaining 238 shares.
  6. On July 27, 2015, AGTCA exercised warrants to purchase 254 shares of Common Stock for $0.14 per share. AGTCA exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 16 of the warrant shares to pay the exercise price and issuing to AGTCA the remaining 238 shares.
  7. On July 27, 2015, AGTCA exercised warrants to purchase 254 shares of Common Stock for $0.14 per share. AGTCA exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 16 of the warrant shares to pay the exercise price and issuing to AGTCA the remaining 238 shares.
  8. On July 27, 2015, AGTCA exercised warrants to purchase 254 shares of Common Stock for $0.14 per share. AGTCA exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 16 of the warrant shares to pay the exercise price and issuing to AGTCA the remaining 238 shares.
  9. On July 27, 2015, AGTCA exercised warrants to purchase 508 shares of Common Stock for $0.14 per share. AGTCA exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 32 of the warrant shares to pay the exercise price and issuing to AGTCA the remaining 476 shares.
  10. Noubar B. Afeyan, Ph.D. is the general partner of Atlast LP and may be deemed to beneficially own the securities held by Atlast LP. Dr. Afeyan disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
  11. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are managers of Flagship Ventures 2007 General Partner LLC, which is the general partner of Flagship Ventures Fund 2007, L.P., and may be deemed to beneficially own the securities held by Flagship Ventures Fund 2007, L.P. Each of Dr. Afeyan and Mr. Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
  12. This warrant is immediately exercisable.